Geron reported $486.34M in Current Assets for its fiscal quarter ending in June of 2026.





Current Assets Change Date
Amgen USD 34.96B 3.49B Jun/2026
Bio Techne USD 744.4M 56.35M Jun/2026
Cassava Sciences USD 87.96M 9.74M Mar/2026
Cytokinetics USD 1.21B 369.02M Jun/2026
Exelixis USD 1.25B 42.18M Jun/2026
Genmab DKK 2.8B 228M Jun/2026
Geron USD 486.34M 12.19M Jun/2026
Gilead Sciences USD 12.53B 6.11B Jun/2026
Incyte USD 6.03B 542.31M Jun/2026
MacroGenics USD 321.69M 139.16M Jun/2026
Novartis USD 27.35B 744M Jun/2026
Novavax USD 771.1M 79.72M Jun/2026